JACC:GATA3阳性巨噬细胞在心梗后重塑中的作用研究

2018-08-22 MedSci MedSci原创

巨噬细胞在心血管疾病的病理发生过程中起到重要作用。本研究的目的旨在探究GATA3阳性巨噬细胞在心梗后调节心脏功能方面的作用。本研究的小鼠模型为骨髓特异性敲除GATA3小鼠(mGATA3KO),心梗建模后,通过超声心动图对其进行心功能评估。结果发现,急性心梗建模后,GATA3阳性巨噬细胞在梗死区域快速聚集,GATA3阳性巨噬细胞的减少可以明显提高心梗后的心脏功能,这种心功能的改善与mGATA3KO小

巨噬细胞在血管疾病的病理发生过程中起到重要作用。本研究的目的旨在探究GATA3阳性巨噬细胞在心梗后调节心脏功能方面的作用。

本研究的小鼠模型为骨髓特异性敲除GATA3小鼠(mGATA3KO),心梗建模后,通过超声心动图对其进行心功能评估。结果发现,急性心梗建模后,GATA3阳性巨噬细胞在梗死区域快速聚集,GATA3阳性巨噬细胞的减少可以明显提高心梗后的心脏功能,这种心功能的改善与mGATA3KO小鼠心肌促炎症的Ly6Chi单核细胞数量增多相关,血清学分析结果显示在心梗前后两组小鼠的血清生长因子和细胞因子无明显变化。在体外培养的巨噬细胞中,GATA3可以被白介素4特异性激活,另外,巨噬细胞的GATA3可以降低精氨酸酶-1的表达。

研究结果显示,GATA3阳性巨噬细胞在心梗后心脏重塑中起到负面作用,该细胞的减少可以改善心梗后的心功能。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854135, encodeId=06f9185413598, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 25 15:06:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053414, encodeId=dae12053414c1, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Mar 19 02:06:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325942, encodeId=32b31325942cf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466059, encodeId=efe714660594e, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340286, encodeId=574934028646, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 23 07:15:31 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2019-06-25 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854135, encodeId=06f9185413598, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 25 15:06:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053414, encodeId=dae12053414c1, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Mar 19 02:06:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325942, encodeId=32b31325942cf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466059, encodeId=efe714660594e, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340286, encodeId=574934028646, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 23 07:15:31 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2019-03-19 lfyang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854135, encodeId=06f9185413598, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 25 15:06:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053414, encodeId=dae12053414c1, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Mar 19 02:06:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325942, encodeId=32b31325942cf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466059, encodeId=efe714660594e, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340286, encodeId=574934028646, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 23 07:15:31 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2018-08-24 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854135, encodeId=06f9185413598, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 25 15:06:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053414, encodeId=dae12053414c1, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Mar 19 02:06:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325942, encodeId=32b31325942cf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466059, encodeId=efe714660594e, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340286, encodeId=574934028646, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 23 07:15:31 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2018-08-24 bbjsj_1981
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854135, encodeId=06f9185413598, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jun 25 15:06:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2053414, encodeId=dae12053414c1, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue Mar 19 02:06:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325942, encodeId=32b31325942cf, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466059, encodeId=efe714660594e, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Fri Aug 24 04:06:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340286, encodeId=574934028646, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 23 07:15:31 CST 2018, time=2018-08-23, status=1, ipAttribution=)]
    2018-08-23 kafei

    学习了谢谢

    0

相关资讯

JAMA:老年人心血管健康水平与痴呆风险研究

研究认为,高龄老人保持健康的心血管水平可显著降低其后继痴呆及认知衰退风险

JACC:依度沙班在亚洲房颤患者中的安全和有效性研究

目前,对于亚洲房颤患者,依度沙班在预防出血和卒中风险方面是否优于华法林尚不清楚。本研究的目的旨在评估依度沙班和华法林在韩国房颤患者中的安全性和有效性。通过韩国国家健康数据库,本研究纳入了4200名服用依度沙班和31565名服用华法林的房颤患者,并分析其缺血性卒中、脑出血(ICH)、胃肠出血、主要出血事件和全因死亡风险。通过倾向性评分匹配,本研究最终以1:3比较了4061名服用依度沙班和12183名

JACC:Takotsubo综合征的远期预后研究

目前,由于临床资料的局限性,关于Takotsubo综合征(TTS)的远期预后尚不清楚。本研究的目的旨在比较和评估TTS和急性冠脉综合征(ACS)患者的预后,并基于不同的触发因素评估TTS的短期和长期预后情况。本研究纳入了1613名TTS患者,并将其与年龄和性别相匹配的ACS患者进行预后情况的比较。在1613名TTS患者中,有485名(30%)患者的触发因素为情感因素,630名(39%)患者的触发因

盘点:2018年度心血管相关指南文献汇总(一)

【盘点】2018年度心血管相关指南文献汇总(一)

Circulation:他汀类药物降低甘油三酯脂蛋白胆固醇的同时亦可降低心血管疾病风险

孟德尔随机数据表明,终身高甘油三酯脂蛋白胆固醇(TRL-C)的遗传决定因素与心血管疾病息息相关,因此可能是潜在的治疗靶点。在服用他汀类药物的患者中,TRL-C与心血管风险的相关性尚不明确。现研究人员对TRL-C和心血管风险之间的关系以及这种风险在他汀类药物治疗的患者中是否会发生改变进行评估。本试验招募冠心病和低密度脂蛋白胆固醇(LDL-C)水平在130-25-mg/dL的患者,进行8周的磨合期,予

Circulation:心血管疾病患者的癌症风险较高?未必!

在社区观察性研究中,有证据显示,心血管疾病与较高的癌症发病率有关。2013年,Hasin等人的研究表明,心力衰竭和后续确诊癌症存在联系。这些发现在对心肌梗死人群的前瞻性队列研究中得到重现,丹麦的大规模心力衰竭队列研究中也观察到类似结果。然而,值得注意的是,这些流行病学研究并未区分射血分数保留型心力衰竭与射血分数降低型心力衰竭对这种相关性的影响差异。